Bristol-Myers Squibb Co Stock Price, News & Analysis

Bristol Myers Squibb (BMY) announced three-year results from the CheckMate -743 trial, showing significant survival benefits for patients with unresectable malignant pleural mesothelioma treated with Opdivo (nivolumab) and Yervoy (ipilimumab) compared to chemotherapy. After 35.5 months, survival rates were 23% for the immunotherapy group versus 15% for chemotherapy, with median overall survival at 18.1 months versus 14.1 months. The trial demonstrated consistent safety without new signals. These findings will be presented at the 2021 European Society for Medical Oncology Congress.

Bristol Myers Squibb (NYSE: BMY) presented findings at the Heart Failure Society of America Annual Scientific Meeting, indicating that increased mortality risk correlates with worsening New York Heart Association (NYHA) functional class among patients with obstructive hypertrophic cardiomyopathy (HCM). The study, involving 2,495 patients, showed varying mortality rates: 5% for NYHA class I, 9% for class II, and 13% for class III/IV over a median follow-up of 3.9 years. These results underscore the importance of assessing NYHA class in treatment outcomes.

Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.49 per share on its common stock, payable on November 1, 2021, to stockholders of record by October 1, 2021. Additionally, a dividend of $0.50 per share will be paid on its convertible preferred stock on December 1, 2021, for stockholders of record by November 9, 2021. This reflects the company's commitment to returning value to shareholders.

Bristol Myers Squibb (NYSE:BMY) will release its third quarter 2021 financial results on October 27, 2021. The company will host a conference call at 8 a.m. ET to discuss these results, addressing questions from investors and analysts. Both investors and the public can access the live webcast at investor.bms.com, or participate by phone. A replay will be available starting at 11:30 a.m. ET on the same day until November 10, 2021.

Bristol Myers Squibb (NYSE:BMY) employee Mark DeLong is participating in the Coast 2 Coast 4 Cancer cycling event, aiming to raise over $1 million for the V Foundation for Cancer Research. The 3,000-mile ride from Cannon Beach, OR to Long Branch, NJ, which starts today and ends on October 1, involves over 230 riders. Bristol Myers Squibb will match contributions up to $500,000. Since its inception in 2014, the event has raised more than $7.15 million for cancer research.

Bristol Myers Squibb (NYSE: BMY) announced significant data on immunotherapies at ESMO 2021, showcasing long-term survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) in advanced cancers. Five-year results from CheckMate-214 in renal cell carcinoma and three-year updates from CheckMate-743 in malignant pleural mesothelioma highlight the effectiveness of these treatments. Additional data on the LAG-3 blocking antibody relatlimab combined with nivolumab emphasizes its potential in treating metastatic melanoma. These findings reinforce the role of these therapies in improving patient outcomes.

Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Virtual Conference on September 14, 2021, at 8 a.m. ET. Giovanni Caforio, M.D., the CEO, will answer questions about the company during this session. Investors and the public can access the live webcast at investor.bms.com, with an archived version available later that day.

Bristol Myers Squibb (NYSE:BMY) announced that the FDA has accepted its supplemental Biologics License Application for Orencia (abatacept) aimed at preventing acute graft versus host disease (aGvHD) in patients 6 years and older undergoing unrelated donor stem cell transplants. The FDA granted Priority Review, with a PDUFA goal date set for December 23, 2021. The application is backed by results from the Phase 2 ABA2 trial, which showed that Orencia significantly reduced aGvHD severity without increasing disease relapse rates.